OptiBiotix Health PLC Manufacturing agreement with Agropur (0905D)
24 Junio 2019 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 0905D
OptiBiotix Health PLC
24 June 2019
OptiBiotix Health plc
("OptiBiotix")
Manufacturing, supply and profit sharing agreement with Agropur
MSI, LLC
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol, diabetes and skin care, announces it has entered
into a manufacturing, supply and distribution agreement with
Agropur MSI, LLC ("Agropur"). The agreement grants Agropur an
exclusive license to manufacture, supply and distribute
OptiBiotix's SlimBiome(R) weight management technology in the USA,
Canada and Mexico.
Founded in 1938, Agropur is a North American dairy industry
leader with 8,800 employees and sales of $6.7 billion in 2018.
Agropur processes more than 6.2 billion litres of milk per year at
its 39 plants across North America and boasts an impressive
portfolio of brands and products including Natrel, OKA, Iögo,
BiPRO, Agropur Grand Cheddar, Olympic, Farmers, Island Farms,
Québon, ISO Chill and Crino.
SlimBiome(R), an award winning weight management product, will
be supplied by Agropur's Customs Solutions Group
(https://www.agropuringredients.com/custom-solutions/) as a
specialised functional ingredient. It can be incorporated into a
wide range of applications including human nutrition comprising of
food and beverages, dairy, dietary supplements and sports nutrition
with the exception of extruded product in cereal particulates which
is a market segment serviced by Cereal Ingredients, Inc (RNS: 12
December 2017).
This is a strategic step by OptiBiotix to de-risk its supply
chain and extend the market reach of SlimBiome(R) by adding
manufacturing in North America. This will extend the commercial
opportunity for its patented award winning weight management
product into the US weight management market which is estimated to
be worth $72 billion in 2019 (source: BusinessWire.com). Partnering
with an established player with an extensive reach to companies
using high value functional ingredients into their food
applications will allow end users to reduce transport and tariff
costs while shortening lead-times and granting them access to
Agropur's expert advice and capabilities to create value.
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division, commented: "We are pleased to announce the signing of a
manufacturing and supply agreement with Agropur. We chose Agropur
due to their world leading expertise in manufacturing and
distributing specialty ingredients like SlimBiome(R) and their
reputation for supplying high quality products to the food
industry. We believe working with Agropur, and similar partners
around the world, provides the best opportunity of increasing our
global commercial reach and catering to the growing interest we are
seeing in SlimBiome(R) from partners worldwide."
Mike Homewood, VP of Agropur's Custom Solutions Group stated:
"The collaboration with OptiBiotix Health is well-aligned with
Agropur's goal to bring innovation to our customers. The
manufacturing and supply of SlimBiome(R) is a natural fit within
our model of solution-focused ingredients for the food, beverage
and nutrition industries. We look forward to collaborating with
OptiBiotix Health in the North American market."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRSEIFIFFUSEEM
(END) Dow Jones Newswires
June 24, 2019 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024